Qatar PR Network, Online Press Release from qatar and Doha city
 
Healthcare(Healthcare & Medicine)
Filter PR by
  
WCM-Q and International Experts Review Whether Metformin is a Drug for all Diseases
 
WCM-Q and International Experts Review Whether Metformin is a Drug for all Diseases

Doha – March 14, 2023:  Researchers from Weill Cornell Medicine-Qatar (WCM-Q) have, together with colleagues from Canada and the U.S., reviewed whether metformin is a drug that can protect against diseases other than type 2 diabetes. The review was published in Metabolism, a leading journal dedicated to human metabolism research. 

In the late 1950s, metformin was used to treat type 2 diabetes. Today, the drug continues to be the preferred choice for millions of people living with the condition. A collection of encouraging pre-clinical and clinical findings has sparked interest in re-purposing the drug to treat several other diseases, such as COVID-19. 

Titled ‘Metformin: Is it a drug for all reasons and diseases?’ The objectives of the review were to evaluate the putative mechanism(s) of action of metformin, analyze the controversial evidence for metformin’s effectiveness in the treatment of diseases other than type 2 diabetes, assess the reproducibility of the data, and reach an informed conclusion as to whether metformin is a drug for all diseases and reasons.

The review concluded that “the primary clinical benefits of metformin result from its insulin-sensitizing and anti-hyperglycemic effects that secondarily contribute to a reduced risk of a number of diseases and thereby enhancing healthspan.” In addition, there is no evidence to suggest that metformin “exerts significant direct anti-inflammatory effects other than indirectly via its positive effects on glucose metabolism.” 

As such, the anti-inflammatory and endothelial-vascular protective effects of the drug are likely to be the primary reason for health improvements witnessed in COVID-19 patients, especially since the most severely affected patients are clinically obese and carry pre-existing diabetes.

The WCM-Q contributing team included Dr. Chris R. Triggle, professor of pharmacology, Dr. Hong Ding, associate professor of research in pharmacology, Dr. Isra Marei, post-doctoral associate in pharmacology, Dr. Ross MacDonald, librarian of scholarly communications, WCM-Q alumnus Dr. Ibrahim Mohammed, and fourth-year medical student Khalifa Bshesh.

International collaborators included Canada-based Kevin Ye, MSc, department of Biomedical Physiology and Kinesiology, Simon Fraser University, and Dr. Morley D. Hollenberg, professor, department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, in addition to Dr. Michael A. Hill, interim director at Dalton Cardiovascular Research Center, and professor at the department of Medical Pharmacology and Physiology, School of Medicine, University of Missouri, U.S.

Dr. Triggle said: “Reviewed pre-clinical and clinical data highlights the benefits of metformin in protecting against a series of diseases. It is, however, important to also keep in mind that since metformin is not metabolized and is excreted unchanged, the environmental impact of the drug is an emerging issue that has been linked to endocrine disruption in fish. In addition, but based to date on a single study from Denmark that was published in 2022, the drug’s extensive use in type 2 diabetes has also raised concerns over its effects on human reproduction. More studies are therefore needed to determine the full impact of metformin. That said, interest in metformin is likely to continue to grow in the years to come.”

Drs. Ding and Triggle received support from the Biomedical Research Program (BMRP) at WCM-Q, while Dr. Marei was supported by ECRA Award [ECRA02-007-3-006] from the Qatar National Research Fund (a member of Qatar Foundation) and the L’Oréal-UNESCO for Women in Science Middle East Regional Young Talents Program, 2020. 

The findings achieved herein are solely the responsibility of the authors. All authors have declared that there is no conflict of interest.

Posted by : Qatar and Doha City PR Network Editorial Team
Viewed 4892 times
PR Category : Healthcare & Medicine
Posted on : Tuesday, March 14, 2023  4:44:00 PM UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of QatarPRNetwork.com.
Next Story : WCM-Q Symposium Discusses the Future of Healthcare
Email this article Print this article

Share this article with your friends and followers
NewsVine
Back to Section Home

Related Stories



 
 
Most Viewed Press Release posted in the last 7 days
New Year, New Me with essence Products [10634-Views]
Embrace this New Year with Catrice [8306-Views]
Pandora Joins Forces with Marvel for a New Guardians of the Galaxy Collection [7790-Views]
Find a Gift as unique as your Love [6661-Views]
Let's Get Ready with essence Products this Valentines [6316-Views]
Arab Bank Group Reports Net Profits of $544.3 million for 2022, 25% Cash Dividends [5409-Views]
UPS Releases 4Q 2022 Earnings [4718-Views]
Chloé Unveils the New SS23 Eyewear Campaign [4705-Views]
CATRICE Brings Love to Your Look with its Valentine-Ready Products [4379-Views]
Russian Compani will Participate in the 11th Largest International Construction Exhibition - The Big... [4282-Views]
LG Announces 2022 Financial Results [4159-Views]
SAP Announces Q4 and FY 2022 Results [3695-Views]
Bahrain's Al Hashemi Crowned Custodian of the Two Holy Mosques Endurance Cup Champion in AlUla [3596-Views]
Qatar Airways Announces Indian Superstar Deepika Padukone as Global Brand Ambassador [3539-Views]
Air Cargo Closes 2022 Near Pre-Pandemic Levels [2926-Views]
Passenger Demand Recovery Continued on Track in December 2022 and for the Full Year [2768-Views]
Air Cargo Makes a Soft Start to 2023 [2630-Views]
For Everyone that Loves like a Mother [1589-Views]
Mondrian Doha Celebrates the Art of Self-Love with LOVE YOURSELF Campaign Launch [1586-Views]
QIC Group at the InsureTek International Conference & Golden Shield Excellence Awards 2023 [1584-Views]
 
RSS Facebook Twitter LinkedDin QatarPRNetwork.com on Instagram
 
Top Sections
 
Top Stories